BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen

详细信息    查看全文

• 作者：Jung-woo Chae ; Yi Ling Teo ; Han Kiat Ho…
• 关键词：Sunitinib ; SU12662 ; Population pharmacokinetics ; Metastatic renal cell carcinoma ; Attenuated sunitinib dosing regimen ; Body surface area ; ABCB1 polymorphism
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：78
• 期：3
• 页码：623-632
• 全文大小：1,033 KB
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Pharmacology and Toxicology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0843
• 卷排序：78

文摘

PurposeAn attenuated dosing (AD) sunitinib regimen of 37.5 mg daily has been suggested to reduce the toxicity reported with the standard dosing regimen to metastatic renal cell carcinoma (mRCC) patients. The aim of this study was to characterize the population pharmacokinetic (PK) properties of sunitinib and SU12662, the active metabolite, in patients receiving the AD regimen and to ascertain significant covariates influencing PK parameters.